Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA).
Burkitt lymphoma
chemotherapy
global oncology
non-Hodgkin lymphoma
treatment
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
01
10
2018
revised:
04
01
2019
accepted:
07
01
2019
pubmed:
25
1
2019
medline:
18
12
2019
entrez:
25
1
2019
Statut:
ppublish
Résumé
Treating B-non-Hodgkin lymphoma (B-NHL) in lower-income countries is challenging because of imprecise diagnosis, the increased risk of fatal toxicity associated with advanced disease at presentation, and limited supportive care. Central American patients with newly diagnosed stage I or II B-NHL received a modified Berlin-Frankfurt-Münster (BFM) regimen including a prephase (prednisone, cyclophosphamide) followed by A/B/A courses (A: cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate, and intrathecal therapy; B: cyclophosphamide, dexamethasone, doxorubicin, methotrexate, and intrathecal therapy). Those with stage III or IV NHL received additional courses (B/A/B), intensified for stage IV disease by additional vincristine and methotrexate doses. Patients in poor condition received a second prephase treatment before their chemotherapy courses. Between March 2004 and June 2016, of 405 patients with B-NHL, 386 (109 females) were eligible for treatment. Immunohistochemistry was performed in 177 cases (47.4%) and characterized the disease as mature B-cell lymphoma. Stage distribution was as follows: I/II, 31 (8.1%); III, 252 (65.3%); IV, 93 (24.1%); 10 (2.6%) not available. The 3-year overall survival was 70% for the whole group (86% for stages I/II, 75% for stage III, 58% for stage IV). Events included death during induction (34 patients, 8.8%), relapse/progression (46, 11.9%), death in remission (9, 2.3%), second malignancy (1, 0.26%), and death of unknown cause (1, 0.26%). Twenty-three (6%) patients abandoned or refused therapy. Approximately 70% of children with B-NHL from Central America experienced long-term, disease-free survival with a modified BFM schedule. Toxic death and relapse/resistant disease were the main reasons for treatment failure.
Sections du résumé
BACKGROUND
Treating B-non-Hodgkin lymphoma (B-NHL) in lower-income countries is challenging because of imprecise diagnosis, the increased risk of fatal toxicity associated with advanced disease at presentation, and limited supportive care.
PROCEDURE
Central American patients with newly diagnosed stage I or II B-NHL received a modified Berlin-Frankfurt-Münster (BFM) regimen including a prephase (prednisone, cyclophosphamide) followed by A/B/A courses (A: cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate, and intrathecal therapy; B: cyclophosphamide, dexamethasone, doxorubicin, methotrexate, and intrathecal therapy). Those with stage III or IV NHL received additional courses (B/A/B), intensified for stage IV disease by additional vincristine and methotrexate doses. Patients in poor condition received a second prephase treatment before their chemotherapy courses.
RESULTS
Between March 2004 and June 2016, of 405 patients with B-NHL, 386 (109 females) were eligible for treatment. Immunohistochemistry was performed in 177 cases (47.4%) and characterized the disease as mature B-cell lymphoma. Stage distribution was as follows: I/II, 31 (8.1%); III, 252 (65.3%); IV, 93 (24.1%); 10 (2.6%) not available. The 3-year overall survival was 70% for the whole group (86% for stages I/II, 75% for stage III, 58% for stage IV). Events included death during induction (34 patients, 8.8%), relapse/progression (46, 11.9%), death in remission (9, 2.3%), second malignancy (1, 0.26%), and death of unknown cause (1, 0.26%). Twenty-three (6%) patients abandoned or refused therapy.
CONCLUSIONS
Approximately 70% of children with B-NHL from Central America experienced long-term, disease-free survival with a modified BFM schedule. Toxic death and relapse/resistant disease were the main reasons for treatment failure.
Identifiants
pubmed: 30677231
doi: 10.1002/pbc.27621
pmc: PMC6428601
mid: NIHMS1006470
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27621Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : CA21765
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Cancer Epidemiol. 2012 Aug;36(4):e221-6
pubmed: 22552334
Pediatr Blood Cancer. 2007 Apr;48(4):486-90
pubmed: 16883600
Cancer Invest. 2002;20(5-6):626-33
pubmed: 12197217
Cochrane Database Syst Rev. 2014 Oct 30;(10):CD003039
pubmed: 25356786
Br J Haematol. 2016 May;173(4):651-4
pubmed: 27098084
J Clin Oncol. 2015 Sep 20;33(27):2963-74
pubmed: 26304908
Pediatr Blood Cancer. 2014 Jun;61(6):997-1002
pubmed: 24347509
Eur J Haematol. 2006 Nov;77(5):365-71
pubmed: 16879606
Pediatr Blood Cancer. 2013 Mar;60(3):357-62
pubmed: 23192950
Asia Pac J Clin Oncol. 2010 Mar;6(1):49-56
pubmed: 20398038
J Clin Oncol. 2015 Sep 20;33(27):3065-73
pubmed: 26304881
Med Pediatr Oncol. 1997 May;28(5):333-41
pubmed: 9121397
Int J Cancer. 2009 Nov 1;125(9):2144-6
pubmed: 19585496
Int J Cancer. 2016 Sep 15;139(6):1231-40
pubmed: 27136063
Pediatr Blood Cancer. 2004 Oct;43(5):580-6
pubmed: 15382276
J Clin Oncol. 1989 Feb;7(2):186-93
pubmed: 2915234
J Pediatr Hematol Oncol. 2012 Oct;34(7):e266-70
pubmed: 22858572
Pediatr Blood Cancer. 2008 Jun;50(6):1138-42
pubmed: 18213709
Pediatr Hematol Oncol. 2012 Mar;29(2):119-29
pubmed: 22376015
Ann Hematol. 2012 Oct;91(10):1603-11
pubmed: 22584851
J Pediatr Hematol Oncol. 2010 Oct;32(7):e279-84
pubmed: 20736844
Lancet. 2012 Mar 31;379(9822):1234-44
pubmed: 22333947
Infect Agent Cancer. 2014 Jun 10;9:19
pubmed: 24932211
Haematologica. 2015 Jun;100(6):810-7
pubmed: 25724577
Pediatr Blood Cancer. 2011 Apr;56(4):560-7
pubmed: 21298740
J Pediatr Hematol Oncol. 2014 Jul;36(5):395-401
pubmed: 23823112
J Clin Oncol. 2010 Jul 1;28(19):3115-21
pubmed: 20516455
Curr Hematol Malig Rep. 2006 Dec;1(4):230-40
pubmed: 20425318
Pediatr Blood Cancer. 2016 Jan;63(1):78-82
pubmed: 26257093
Blood. 1999 Nov 15;94(10):3294-306
pubmed: 10552938
J Pediatr Hematol Oncol. 2004 Jul;26(7):462-8
pubmed: 15218425
Blood. 2005 Feb 1;105(3):948-58
pubmed: 15486066
Lancet Oncol. 2008 Jun;9(6):512-3
pubmed: 18510986